In Vivo

In Vivo is the leading source for strategies in the life sciences sector, encompassing biopharma, medtech, and diagnostics in a comprehensive format. With a distinct insight into the dynamics influencing global healthcare, In Vivo provides you with the essential context behind industry happenings, enabling you to make informed business choices proactively, negotiate deals with assurance, and spot opportunities that others may overlook. In Vivo offers exclusive interviews with top executives in the industry, along with insightful articles that help you stay ahead of emerging trends and keep updated on the latest in deal-making, marketing, research and development, regulatory, and financial strategies.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

N/A

Country

N/A

Articles

Bristol Myers Squibb ASPIREs For Access In LMICs

Oct 14, 2024 | invivo.citeline.com | Anabel Costa-Ferreira

Interviews Executive Summary BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility. Existing Subscriber? Sign in to continue reading. New to In Vivo? Start a free trial today!
FDA Publishes Updated Roadmap For Advancing Women's Health

Oct 14, 2024 | invivo.citeline.com | Brian Bossetta

Analysis Executive Summary The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to In Vivo? Start a free trial today!
The Anatomy Of Astellas And Poseida's CAR-T Deal

Oct 14, 2024 | invivo.citeline.com | David Wild

Interviews Executive Summary Dealmakers from CAR-T biotech Poseida Therapeutics and Astellas recently sat down with In Vivo to discuss how they reached a $600m deal that combines their technologies and how they plan on moving forward. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to In Vivo? Start a free trial today!
Fusion Talks AZ Deal Making, RTL Innovation, and Canada’s Blossoming Biotech Ecosystem

Oct 14, 2024 | invivo.citeline.com | Jo Shorthouse

Interviews Executive Summary Fusion Pharmaceuticals Inc CEO John Valliant talked to In Vivo about Canadian leadership in radiopharmaceutical innovation, its differentiated approach, and excitement around combination therapies for precision cancer treatments. Source: Shutterstock When AstraZeneca PLC bought Canadian radiopharmaceuticals firm Fusion Pharmaceuticals Inc.
Author Detail

Oct 10, 2024 | invivo.citeline.com | Andrew McConaghie

Acccess Token : Refresh Token : Entitlement Claim : In Vivo is part of Pharma Intelligence UK Limited This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group. Existing Subscriber?
BioBytes: AI-Related Deals in Q3 2024

Oct 9, 2024 | invivo.citeline.com | David Wild

Executive Summary The big news in Q3 2024 was the acquisition of Exscientia by Recursion, which has now expanded its pipeline and gained access to more contracts, but this quarter was also marked by numerous seed rounds and M&As, with the strengthening of existing companies and emergence of new ones into what is becoming a crowded space. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to In Vivo?
Podcast: Noticing Neffy - A ‘Transformative Treatment’ For Type 1 Allergies

Oct 9, 2024 | invivo.citeline.com | Anabel Costa-Ferreira

Interviews Executive Summary Richard Lowenthal, co-founder, and CEO of ARS Pharma, highlights the crucial unmet need for needle-free injections. Challenging issues posed by current epinephrine injectors, In Vivo questions the current and future progression of Neffy. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to In Vivo? Start a free trial today!
Biopharma Dealmaking: All About The Science And Personal Chemistry

Oct 7, 2024 | invivo.citeline.com | Andrew McConaghie

Analysis Executive Summary Business development leaders from AstraZeneca and Novartis and a biotech CEO get frank about what they want from the other side, highlighting the need for transparency during competitive negotiations, plusa shared spark of enthusiasmabout pursuing novel science. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to In Vivo? Start a free trial today!
Combatting Stroke Requires Global Health Systems To Take A Giant Step

Oct 7, 2024 | invivo.citeline.com | Ashley Yeo
Podcast: Alpha-Synuclein Testing Comes of Age

Oct 7, 2024 | invivo.citeline.com | David Wild

Interviews Executive Summary In the latest episode of the In Vivo podcast, Russ Lebovitz, the co-founder and scientist behind San Diego's Amprion Diagnostics, discusses the role alpha-synuclein misfolding plays in neurodegenerative diseases and how early alpha-synuclein testing could mitigate the impacts of conditions ranging from Parkinson's disease to Lewy body dementia. Source: Shutterstock Existing Subscriber?